Effect of Kangaroo Care on Test Weighing
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jan 31, 2020
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of Kangaroo Care, which is a method where a parent holds their baby skin-to-skin, on weight gain, oxygen levels, and heart rate in premature infants. The researchers want to see how this comforting practice during feeding times can help babies thrive while they are in the neonatal intensive care unit (NICU). In the trial, infants will be randomly divided into two groups. One group will receive Kangaroo Care during their first feeding, while the other group will have it during their second feeding. Both groups will be breastfed by their mothers.
To participate in this study, infants must be born between 26 to 36 weeks of pregnancy, weigh at least 1500 grams, and have started oral feeding. They should not have any serious health issues that could affect feeding. Parents who agree to take part will help their babies experience Kangaroo Care during the study. This trial is currently recruiting participants, and it aims to provide valuable insights into how nurturing practices can support the health and growth of premature infants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Agreeing to participate in the study for parents.
- • The inclusion criteria for infants were as follows;
- • Attaining to oral feeding by the physician in the neonatal intensive care unit
- • Being born at 26-36+6 gestational week which is determined according to the mother's last period cycle
- • Being at 32-39+6 postmenstrual week during the time they are included in the study
- • Having body weight of 1500 grams and above
- • Being breastfed at least once
- • Having no health problems other than being preterm
- Exclusion Criteria:
- • The exclusion criteria for infants were as follows;
- • Suffering from gastrointestinal, neurological or genetic diseases (such as necrotizing enterocolitis, intracranial bleeding, hydrocephalia, omphalocele, down syndrome, gastroschisis) and other diseases
- • Having a condition obstructing oral feeding (such as cleft palate, cleft lip, facial muscle paralysis, craniofacial abnormalities etc.)
- • Receiving oxygen support
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Beykoz, Turkey
Patients applied
Trial Officials
Duygu Gözen, Assoc. Prof.
Principal Investigator
Istanbul University Cerrahpaşa Florence Nightingale Faculty of Nursing
Ayhan Taştekin, prof.
Principal Investigator
Istanbul Medipol University, Pediatrics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials